New hope for advanced kidney cancer patients in Second-Line treatment trial
NCT ID NCT07469683
Summary
This study is testing whether adding a new drug called SLC-3010 to an existing cancer drug (axitinib) works better than using axitinib alone. It is for adults with advanced kidney cancer that has worsened after their first treatment. The main goal is to see if the combination helps shrink tumors more effectively and for a longer time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Severance Hospital
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.